Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 933-047-9 | CAS number: 53880-05-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 3 537.5 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An acute oral toxicity study conducted on female rats according to OECD TG 423 revealed no mortalities, no clinical signs and no effects on body weight gain for the limit dose of 2000 mg/kg bw. At necropsy no gross pathological findings were observed. The LD50 cut off was estimated from the flow chart of the OECD TG 423 (2001), Annex 2d, to be 5000 mg/kg bw.
An acute inhalation toxicity study of the substance (80 % in butyl acetate) was conducted in accordance with OECD TG 403 and OECD GD 39. Rats were nose-only exposed to the liquid aerosol of the substance at 0 (butyl acetate control), 460, 1546, 3906, and 4586 mg/m³ (actual concentrations of the test substance 80 % in butyl acetate). The respirability of the aerosol was adequate, i.e. the mass median aerodynamic diameter (MMAD) was smaller than 2.5 µm and the geometric standard deviation (GSD) 1.7-2.4.
Mortality did not occur at concentrations up to 1546 mg/m³. Rats exposed at higher concentrations showed evidence of respiratory irritation with mortality patterns typical of an irritation-related acute lung edema. The LC50 was determined to be 4090 mg/m³ (actual concentration of the substance 80 % in butyl acetate); LC50 for the non-volatile fractions of the test article (based on gravimetric concentrations) = 3537.5 mg/m³. The latter value was used for hazard assessment, since the non-volatile fraction of the test article mainly reflects the substance itself, without the proportion of the solvent, that was contained in the test-substance due to technical reasons.
An acute dermal toxicity study is not available for the substance. Based on weight of evidence an assessment of the acute dermal toxicity is possible.
IPDI oligomers, allophanate type, has an average molecular weight of about 750 g/mol, which is not favourable for dermal absorption. Due to the reactive isocyanate groups the substance is unstable towards nucleophiles, e.g. water or alcohols.
For acute and repeated (see chapter Repeated dose toxicity) inhalation the available studies reveal indications for “port-of-entry” irritant toxicity, which is typical for aliphatic isocyanates [1]. No systemic availability can be concluded from the results. This is also true for the acute oral toxicity study, as no effects at all were observed up to the maximum administered dose of 2000 mg/kg. Overall, with the exception of skin sensitisation (the LLNA exhibited a potential for skin sensitization and an acute irritation/inflammation response) none of the available studies reveal indications for systemic availability, however, due to the positive LLNA it cannot be completely ruled out. Nevertheless, despite the irritant effect which may diminish the protective function of the epidermis (worst case assumption) it is not expected for a substance with such a profile (i.e. irritancy at the port-of-entry due to isocyanate-reactivity) that systemic availability after dermal exposure is higher than after oral exposure.
Summarizing, with the mode of action outlined above, the oral LD50 > 2000 mg/kg and no signs of toxicity at all after oral exposure, it is not expected that testing on acute dermal toxicity would reveal adverse systemic effects. Local effects were already assessed by the respective skin irritation/corrosion studies. Thus, based on the weight of evidence a conclusion can be drawn that for acute dermal toxicity no hazard is expected. This is in line with recent publications[2][3], in which the benefit of performing acute dermal toxicity studies is in general questioned, in particular if there are no indications for a substance to be hazardous via the oral route. The European Competent Authorities for REACH and CLP (Caracal) have already acknowledged that. The committee agreed on proposals to amend REACH Annex VIII (8.5.3) as such that substances with no acute oral toxicity up to 2000 mg/kg would not require acute dermal toxicity data.[4][5]
[1] Brochhagen, Isocyanates, in: O. Hutzinger (Ed.), The Handbook of Environmental Chemistry, Vol. 3, Part G, Springer Verlag, Berlin, 1991
[2] Moore, Regulatory Toxicology and Pharmacology, 2013, 66, 30-37
[3] Creton, St. et al, Critical reviews in Toxicology, 2010, Vol. 40 No.1, pages 50-83
[4] http://www.piscltd.org.uk/wp-content/uploads/2014/09/20140714-110033_CA_61_2014-Acute-toxicity-testing-proposal.pdf
[5] https://chemicalwatch.com/20557/caracal-agrees-need-to-drop-acute-dermal-toxicity-tests
Justification for classification or non-classification
According to Regulation (EC) No 1272/2008, Annex I, the substance has to be classified as Acute Tox. 4 (H332: Harmful if inhaled).
According to Regulation (EC) No 1272/2008, Annex I, no classification is warranted for acute oral or dermal toxicity. With respect to dermal toxicity it is not assumed that testing on this endpoint would lead to a hazard classification for the substance taking into account the mode of action outlined above, the oral LD50 >2000 mg/kg, no signs of toxicity at all after oral exposure, and the expectation that systemic availability after dermal exposure will not exceed systemic availability after oral exposure. Therefore, it can be concluded that the available data are conclusive for non-classification for acute dermal toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.